KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Short term Debt: 2013-2025

Historic Short term Debt for Travere Therapeutics (TVTX) over the last 5 years, with Jun 2025 value amounting to $68.8 million.

  • Travere Therapeutics' Short term Debt was N/A to $68.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $68.8 million, marking a year-over-year change of. This contributed to the annual value of $68.7 million for FY2024, which is N/A change from last year.
  • Per Travere Therapeutics' latest filing, its Short term Debt stood at $68.8 million for Q2 2025, which was up 0.12% from $68.8 million recorded in Q1 2025.
  • Over the past 5 years, Travere Therapeutics' Short term Debt peaked at $68.8 million during Q2 2025, and registered a low of $6.9 million during Q1 2023.
  • Moreover, its 3-year median value for Short term Debt was $68.6 million (2024), whereas its average is $48.1 million.
  • Data for Travere Therapeutics' Short term Debt shows a maximum YoY plummeted of 57.47% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Travere Therapeutics' Short term Debt stood at $7.4 million in 2021, then declined by 5.41% to $7.0 million in 2022, then decreased by 5.48% to $6.9 million in 2023, then reached $68.7 million in 2024, then reached $68.8 million in 2025.
  • Its last three reported values are $68.8 million in Q2 2025, $68.8 million for Q1 2025, and $68.7 million during Q4 2024.